Work

Initial results from a phase I, open-label, dose escalation study of the oral BRAF inhibitor LGX818 in patients with BRAF V600 mutant advanced or metastatic melanoma.

Year: 2013

Type: conference-abstract

Source: Journal of Clinical Oncology

DOI: 10.1200/jco.2013.31.15_suppl.9028

Authors: Reinhard Dummer, Caroline Robert, Marta Nyakas, Grant A. McArthur, Ragini Reiney Kudchadkar, Carlos Gomez-Roca, Ryan J. Sullivan, Keith Flaherty, Carla Murer, Daniela Michel, Zhongwen Tang, Laure A. De Parseval, Jean-Pierre Delord

Institutions: University Hospital Zurich, Institut Gustave Roussy, Oslo University Hospital, Peter MacCallum Cancer Centre, Moffitt Cancer Center, Institut Claudius Regaud, Massachusetts General Hospital, Harvard University, Novartis (Switzerland), Novartis (United States)

Language: English

Topic: Melanoma and MAPK Pathways

Subfield: Molecular Biology

Field: Biochemistry, Genetics and Molecular Biology

Domain: Life Sciences

SDG: Good health and well-being

Open Access status: closed

OpenAlex ID: W2520540679

Cites:

Cited by: 45

Related to: 10